7 ALS Headlines
Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on its application for orphan drug designation for CDNF as a potential treatment for amyotrophic lateral sclerosis (ALS).
A positive opinion is the first step toward orphan drug designation which, in Europe, is issued by the European Commission.
The California Institute for Regenerative Medicine (CIRM)’s Independent Citizens Oversight Committee has approved a $6.3 million grant to fund a research team’s work into a new human embryonic stem cell-based therapy, involving astrocytes, to rescue and restore neurons damaged as a consequence of amyotrophic lateral sclerosis (ALS).
In this video, find out more about the work of the Les Turner ALS Foundation.
ALS can be very difficult to diagnose since there isn’t a specific procedure or test to ultimately establish the ALS diagnosis. It is only through several diagnostic tests (often used to rule out other diseases which mimic ALS) and a thorough clinical examination that a diagnosis can be established.
Yumanity Therapeutics has recently licensed a prodrug invented at the University of Arizona (UA), adding it to the company’s expanding platform of potential therapies for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS).
In this article, learn five misconceptions about ALS.
A-myo-trophic comes from the Greek language. “A” means no. “Myo” is referring to the muscle, and “Trophic” means nourishment – All put together: “No muscle nourishment.”